Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.
about
Advances in the autologous and allogeneic transplantation strategies for multiple myelomaDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple MyelomaCombining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Plasma cell leukemia.Novel therapies in multiple myeloma for newly diagnosed nontransplant candidatesIdentification and expression of MMSA-8, and its clinical significance in multiple myeloma.Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myelomaThe t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significanceHow we manage autologous stem cell transplantation for patients with multiple myelomaInput of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.Microsieve lab-chip device for rapid enumeration and fluorescence in situ hybridization of circulating tumor cells.The molecular classification of multiple myelomaRetrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma.Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsCombination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-rGenetics of multiple myeloma: another heterogeneity level?Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experienceImpact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue.Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system.A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.Cure of multiple myeloma -- more hype, less reality.Genetic events in the pathogenesis of multiple myeloma.Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.Microarray-based understanding of normal and malignant plasma cells.Clinical implications of chromosomal abnormalities in multiple myeloma.Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myelomaImproving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
P2860
Q27014801-62C2417B-859A-4230-AB64-F27300AA826CQ27692033-A25CCD8D-8290-434F-9A36-F30630C25A80Q28074490-669CAAA6-4FED-4E8C-8AAB-B5F61C9B0C33Q30571858-0A045C85-0BA1-4246-924D-8741BBA41DFEQ31154933-013A3C1D-5C07-40A4-A122-CCA88CEA4EF5Q33393995-E4E81A9E-A2B1-45FB-B5E7-8B7AA5FB0CCAQ33639796-BD0BE2A2-EA98-4096-8879-3422847EB316Q33721123-16E05DC9-602F-49F1-855C-7D06623994C8Q33816012-770713E3-E045-4238-9D99-F27AABCD3392Q33952861-2BAEAF6D-6FDA-432B-813E-F980BC81F333Q34019581-4ADC956D-9E5B-416D-B766-F75523875663Q34022979-7E0717B5-9A84-4791-AFB9-788E0FAD97F3Q34063353-E249FBDF-5AED-4B18-95C9-E4198184CCCFQ34115051-EFF7CAA2-4F86-43E9-891E-02FC505C11D5Q34241661-5B5CEABF-681D-4666-A7B5-963959C84337Q34296442-1AA6174F-F991-4B05-A3FE-7A046A1827D1Q34316559-0A849CF2-925A-438E-9F20-21A9DDD8C088Q34396921-929D76E0-D864-4173-8378-D3E781C3CBCEQ34530992-A4036B56-32F0-4032-B1A9-FAF28FEEDA7EQ34993904-88C5CB01-74A3-4172-8FE5-2EEEFDD08DC3Q35081172-FECD8500-9337-456B-9323-9514C5AE42AAQ35180069-8CD66136-0C82-4CCA-BB83-16642CEEB17CQ35197437-02E57F47-6B90-458F-8374-F424028BAA2CQ35220653-540A9A8B-3C98-4DE8-A70F-43BB4B22D8E4Q35265979-2BF9E395-16D0-4D6E-A64C-D7CB50C0AE7AQ35651050-EC31302C-5E3D-44BA-B5E9-8C013E458D8EQ35678607-186A961C-965E-4186-AFF7-74C73121B267Q35802414-26ABB5DF-00C0-4E6E-A691-E58D1E2654F7Q35849219-CEB7FAC3-968E-4D72-94C1-FB42E55B54E5Q35849614-EEE3E20C-8D17-4619-B84E-FC27B974BDB0Q35984702-5FF5378B-8359-4226-A1B4-E73E81B998FFQ36301128-CC1ED74C-ADB0-4C03-BA6A-B19310DA5476Q36380235-C7819866-C31D-47FC-A168-819688151BB9Q36382187-2DA8A1C9-A915-4AAF-AB27-98BAA5E7607FQ36407446-898DA569-03AE-4CD8-A5B0-2FC0228760D4Q36453354-5D643E7E-DF28-4308-AE00-C94E2C8C1D28Q36497416-9F3850BF-C584-453D-8829-1205944F1234Q36525224-081F160F-C78A-4139-B84C-F68CBF946885Q36572310-0FDB96AA-AF57-4B8C-8FB7-5BFF846A6764Q36595290-1D776C03-DBEE-4743-9802-DF5EAB555985
P2860
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Clinical implications of t(11; ...... reated with high-dose therapy.
@ast
Clinical implications of t(11; ...... reated with high-dose therapy.
@en
type
label
Clinical implications of t(11; ...... reated with high-dose therapy.
@ast
Clinical implications of t(11; ...... reated with high-dose therapy.
@en
prefLabel
Clinical implications of t(11; ...... reated with high-dose therapy.
@ast
Clinical implications of t(11; ...... reated with high-dose therapy.
@en
P2093
P2860
P50
P1433
P1476
Clinical implications of t(11; ...... reated with high-dose therapy.
@en
P2093
Greg J Ahmann
Kimberly J Henderson
Mark R Litzow
Philip R Greipp
Rafael Fonseca
Scott A Van Wier
P2860
P304
P356
10.1182/BLOOD-2005-04-1411
P407
P577
2005-06-23T00:00:00Z